Efficacy and safety of keverprazan compared to lansoprazole in the treatment of duodenal ulcer: a phase III, randomised, double-blind, multicentre trial.

Nian Di TanXin-Pu MiaoAi-Jun LiaoCheng-Xia LiuHao WuHong-Hui ChenFang-Fang LiQing-Hong GuoSheng-Bao LiYan-Ping TangMin XiaYou-Li LiuXing LiHui-Xin ChenXiao-Wei LiuYan ZhangZhen-Yu ZhangMin-Hu ChenYing-Lian Xiao

Published in: Clinical and translational gastroenterology (2023)

Keverprazan 20 mg had a good safety profile and was non-inferior to lansoprazole 30 mg once daily for DU healing.

Keyphrases

phase iii
double blind
placebo controlled
clinical trial
open label
phase ii
study protocol
physical activity
randomized controlled trial
cross sectional